The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.

Autor: Zelenetz, Andrew D., Jurczak, Wojciech, Ribrag, Vincent, Linton, Kim, Collins, Graham P., Jiménez, Javier L., Bishton, Mark, Dholaria, Bhagirathbhai, Mengarelli, Andrea, Phillips, Tycel J., Sungala, Nagendraprasad, Musuraca, Gerardo, Sheehy, Oonagh, Van Den Neste, Eric, Odera, Mitsuhiko, Miao, Lu, Gold, Daniel P., Ghalie, Richard G., Zinzani, Pier L.
Zdroj: HemaSphere; Aug2024, Vol. 8 Issue 8, p1-10, 10p
Databáze: Complementary Index
Externí odkaz: